Biomolecules & Therapeutics

The Korean Society of Applied Pharmacology (한국응용약물학회)
권호 표지
DOI QR코드

DOI QR Code

Synergic Effect of Trimebutine Combined with Mosapride on Gastrointestinal Dysfunction and Visceral Pain Induced in Stress Models

  • Received : 2010.08.25
  • Accepted : 2010.09.18
  • Published : 2011.01.31
Download PDF
⟨ Previous Next ⟩

Abstract

The present study was undertaken to determine whether combined treatment with prokinetic trimebutine and mosapride has a synergic effect on gastrointestinal motility and visceral pain associated with gastrointestinal dysfunction. To develop effective gastroprokinetic agents with greater potencies than trimebutine or mosapride for the treatment of gastrointestinal tract disease, a mixture of trimebutine and mosapride was designed and prepared. In the present study, treatment with trimebutine alone showed a dose-dependent effect on propelling movements of normal small and large intestine in mice, whereas mosapride effected only small intestine motility. Co-administration of trimebutine with mosapride, a well-established prokinetic drug, produced a synergistic influence on normal small intestine motility, but demonstrated an unclear effect on large intestine motility, with a slight tendency to reduce the propelling time. In a stress model, the small and large intestine motilities were significantly decreased. The reduction of intestine motility was restored to a normal level and the restoring effect was more pronounced in the combined treatment with trimebutine plus mosapride than treatment with trimebutine or mosapride alone. Furthermore, treatment with trimebutine plus mosapride significantly decreased acute visceral pain which was not controlled by trimebutine or mosapride alone. These data suggest that combination therapy with trimebutine plus mosapride has a synergic effect on small and large intestine motility and visceral pain control in gastrointestinal disorders.

Keywords

References

  1. Boyle, G., Mounsey, A. and Crowell, K. (2009) Clinical inquiries: whatis the role of prokinetic agents for constipation? J. Fam. Pract. 58,220d-220f.
  2. Chicella, M. F., Batres, L. A., Heesters, M. S. and Dice, J. E. (2005)Prokinetic drug therapy in children: a review of current options.Ann. Pharmacother. 39, 706-711. https://doi.org/10.1345/aph.1E411
  3. Chua, A. S., Bekkering, M., Rovati, L. C. and Keeling, P. W. (1994)Clinical efficacy and prokinetic effect of the CCK-A antagonist loxiglumidein nonulcer dyspepsia. Ann. N. Y. Acad. Sci. 713, 451-453. https://doi.org/10.1111/j.1749-6632.1994.tb44124.x
  4. Curran, M. P. and Robinson, D. M. (2008) Mosapride in gastrointestinaldisorders. Drugs 68, 981-991. https://doi.org/10.2165/00003495-200868070-00007
  5. Delco, M. L., Nieto, J. E., Craigmill, A. L., Stanley, S. D. and Snyder,J. R. (2007) Pharmacokinetics and in vitro effects of tegaserod,a serotonin 5-hydroxytryptamine 4 (5-HT4) receptor agonist withprokinetic activity in horses. Vet. Ther. 8, 77-87.
  6. Delvaux, M. and Wingate, D. (1997) Trimebutine: mechanism of action,effects on gastrointestinal function and clinical results. J. Int.Med. Res. 25, 225-246.
  7. Dubinsky, B., Gebre-Mariam, S., Capetola, R. J. and Rosenthale, M.E. (1987) The antialgesic drugs: human therapeutic correlates oftheir potency in laboratory animal models of hyperalgesia. AgentsActions 20, 50-60. https://doi.org/10.1007/BF01965625
  8. Greenwood, B. and Davison, J. S. (1987) The relationship betweengastrointestinal motility and secretion. Am. J. Physiol. 252, G1-7.
  9. Hawkyard, C. V. and Koerner, R. J. (2007) The use of erythromycinas a gastrointestinal prokinetic agent in adult critical care: benefitsversus risks. J. Antimicrob. Chemother. 59, 347-358. https://doi.org/10.1093/jac/dkl537
  10. Holzer, P. (2004) Opioids and opioid receptors in the enteric nervoussystem: from a problem in opioid analgesia to a possible new prokinetictherapy in humans. Neurosci. Lett. 361, 192-195. https://doi.org/10.1016/j.neulet.2003.12.004
  11. Kii, Y., Nakatsuji, K., Nose, I., Yabuuchi, M., Mizuki, Y. and Ito, T. (2001)Effects of 5-HT(4) receptor agonists, cisapride and mosapride citrateon electrocardiogram in anaesthetized rats and guinea-pigsand conscious cats. Pharmacol. Toxicol. 89, 96-103. https://doi.org/10.1034/j.1600-0773.2001.d01-142.x
  12. Koop, H., Monnikes, H., Koop, I., Dionysius, J., Schwarz, C. and Arnold,R. (1986) Effect of the prokinetic drug cisapride on gastrointestinalhormone release. Scand. J. Gastroenterol. 21, 907-913. https://doi.org/10.3109/00365528608996394
  13. Kountouras, J., Chatzopoulos, D., Zavos, C., Boura, P., Venizelos, J.and Kalis, A. (2002) Efficacy of trimebutine therapy in patients withgastroesophageal reflux disease and irritable bowel syndrome.Hepatogastroenterology 49, 193-197.
  14. Luttecke, K. (1978) A trial of trimebutine in spastic colon. J. Int. Med.Res. 6, 86-88. https://doi.org/10.1177/030006057800600202
  15. Matsue, T., Yamato, S. and Umeda, N. (1990) Mechanism of action oftrimebutine maleate on gastro-colic reflex in patients with irritablebowel syndrome. Nippon Heikatsukin Gakkai Zasshi 26, 89-92.
  16. Mine, Y., Yoshikawa, T., Oku, S., Nagai, R., Yoshida, N. and Hosoki,K. (1997) Comparison of effect of mosapride citrate and existing5-HT4 receptor agonists on gastrointestinal motility in vivo and invitro. J. Pharmacol. Exp. Ther. 283, 1000-1008.
  17. Nosaka, K., Takenaga, H., Magaribuchi, T. and Tamaki, H. (1984) Effectsof trimebutine maleate (TM-906) on the gastrointestinal motilityin anesthetized dogs. Nippon Heikatsukin Gakkai Zasshi 20,407-412. https://doi.org/10.1540/jsmr1965.20.407
  18. Odaka, T., Suzuki, T., Seza, A., Yamaguchi, T. and Saisho, H. (2006)Serotonin 5- HT4 receptor agonist (mosapride citrate). NipponRinsho 64, 1491-1494.
  19. Reynolds, J. C. and Putnam, P. E. (1992) Prokinetic agents. Gastroenterol.Clin. North Am. 21, 567-596.
  20. Roman, F. J., Lanet, S., Hamon, J., Brunelle, G., Maurin, A., Champeroux,P., Richard, S., Alessandri, N. and Gola, M. (1999) Pharmacologicalproperties of trimebutine and N-monodesmethyltrimebutine.J. Pharmacol. Exp. Ther. 289, 1391-1397.
  21. Sakurai-Yamashita, Y., Takada, K., Takemura, K., Yamashita, K., Enjoji,A., Kanematsu, T. and Taniyama, K. (1999) Ability of mosaprideto bind to 5-HT4 receptor in the human stomach. Jpn. J. Pharmacol.79, 493-496. https://doi.org/10.1254/jjp.79.493
  22. Shimada, T., Kurachi, Y., Terano, A., Hamada, E. and Sugimoto, T.(1990) Trimebutine maleate has inhibitory effects on the voltage-dependentCa2+ inward current and other membrane currents inintestinal smooth muscle cells. Gastroenterol. Jpn. 25, 175-179.
  23. Takagi, K. and Okabe, S. (1968) The effects of drugs on the productionand recovery processes of the stress ulcer. Jpn. J. Pharmacol.18, 9-18. https://doi.org/10.1254/jjp.18.9
  24. Takenaga, H., Magaribuchi, T. and Tamaki, H. (1984a) Effects of trimebutinemaleate (TM-906) on the smooth muscles of isolated guineapig gallbladder. Jpn. J. Pharmacol. 35, 439-443. https://doi.org/10.1254/jjp.35.439
  25. Takenaga, H., Magaribuchi, T. and Tamaki, H. (1984b) Effects of trimebutinemaleate (TM-906) on the spontaneous contraction of isolatedguinea pig colon. Jpn. J. Pharmacol. 34, 177-181. https://doi.org/10.1254/jjp.34.177
  26. Takenaga, H., Magaribuchi, T. and Tamaki, H. (1986) Effects of trimebutinemaleate (TM-906) on the spontaneous contraction of isolatedduodenum and ileum in both guinea pigs and rabbits. Jpn. J.Pharmacol. 40, 13-20. https://doi.org/10.1254/jjp.40.13
  27. Tanaka, M. (1998) Gastric ulcer, motility, and trimebutine. J. Gastroenterol.33, 916-917. https://doi.org/10.1007/s005350050201
  28. Uchiyama, M., Iwafuchi, M., Yagi, M., Iinuma, Y., Kanada, S., Ohtaki,M. and Homma, S. (2000) Effects of trimebutine on intestinal motilityafter massive small bowel resection. J. Smooth. Muscle. Res.36, 117-126. https://doi.org/10.1540/jsmr.36.117
  29. Washabau, R. J. (2003) Gastrointestinal motility disorders and gastrointestinalprokinetic therapy. Vet. Clin. North Am. Small Anim.Pract. 33, 1007-1028, vi. https://doi.org/10.1016/S0195-5616(03)00076-7
  30. Wingate, D., Hongo, M., Kellow, J., Lindberg, G. and Smout, A. (2002)Disorders of gastrointestinal motility: towards a new classification.J. Gastroenterol. Hepatol. 17(Suppl), S1-14. https://doi.org/10.1046/j.1440-1746.17.s1.7.x
  31. Yoshida, N., Ito, T., Karasawa, T. and Itoh, Z. (1991) AS-4370, a newgastrokinetic agent, enhances upper gastrointestinal motor activityin conscious dogs. J. Pharmacol. Exp. Ther. 257, 781-787.
  32. Yoshida, N., Omoya, H., Kato, S. and Ito, T. (1993) Pharmacologicaleffects of the new gastroprokinetic agent mosapride citrate and itsmetabolites in experimental animals. Arzneimittelforschung 43,1078-1083.
  33. Zenilman, M. E. (1993) Origin and control of gastrointestinal motility.Surg. Clin. North. Am. 73, 1081-1099.
  34. Zhang, H. Q., Zhou, C. H. and Wu, Y. Q. (2005) Effect of emodin onsmall intestinal peristalsis of mice and relevant mechanism. WorldJ. Gastroenterol. 11, 3147-3150. https://doi.org/10.3748/wjg.v11.i20.3147